InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,764.02
(
-0.21%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jb_118 post# 1060

Wednesday, 10/04/2006 7:30:08 PM

Wednesday, October 04, 2006 7:30:08 PM

Post# of 19309
Thanks for posting the article. The crux of it is this excerpt:

>>
…it's not clear yet that Symphogen's technique will pass regulatory authorities' standards for consistency. “The authorities are going to ask them to characterize the antibodies individually,” says Yann Echelard, vice president of R&D at GTC Biotherapeutics in Framingham, Massachusetts. If they can't put the same amount of each antibody into every dose, “that's a showstopper for getting approved,” he says.
<<

If GTC had a long road to regulatory approval for its production platform, it’s reasonable to assume that the polyclonal companies will encounter a longer road.

Moreover, for a variety of practical reasons, animal serum does not begin to compare to milk as a source for therapeutic proteins.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up